Cantor Fitzgerald Reiterates “Overweight” Rating for Jasper Therapeutics (NASDAQ:JSPR)

Jasper Therapeutics (NASDAQ:JSPR)‘s stock had its “overweight” rating restated by stock analysts at Cantor Fitzgerald in a research report issued on Monday, Benzinga reports.

Several other brokerages also recently commented on JSPR. JMP Securities started coverage on shares of Jasper Therapeutics in a report on Monday. They set an “outperform” rating and a $70.00 target price for the company. Stifel Nicolaus started coverage on Jasper Therapeutics in a research report on Thursday, June 27th. They issued a “buy” rating and a $86.00 target price on the stock. BTIG Research began coverage on Jasper Therapeutics in a report on Monday, July 8th. They set a “buy” rating and a $90.00 price target for the company. HC Wainwright restated a “buy” rating and issued a $65.00 price target on shares of Jasper Therapeutics in a research note on Tuesday, August 13th. Finally, Evercore ISI reiterated an “outperform” rating and set a $65.00 price objective on shares of Jasper Therapeutics in a research report on Monday, August 26th. Ten analysts have rated the stock with a buy rating, According to MarketBeat, the stock has a consensus rating of “Buy” and an average target price of $73.00.

Jasper Therapeutics Stock Performance

JSPR opened at $20.29 on Monday. The business’s 50-day simple moving average is $19.46 and its 200 day simple moving average is $22.68. The firm has a market capitalization of $306.38 million, a PE ratio of -3.60 and a beta of 2.22. Jasper Therapeutics has a 52-week low of $4.00 and a 52-week high of $31.01.

Jasper Therapeutics (NASDAQ:JSPR) last announced its quarterly earnings data on Tuesday, August 13th. The company reported ($0.97) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.09) by $0.12. On average, research analysts forecast that Jasper Therapeutics will post -4.16 earnings per share for the current year.

Institutional Investors Weigh In On Jasper Therapeutics

A number of large investors have recently bought and sold shares of the company. Ieq Capital LLC acquired a new stake in shares of Jasper Therapeutics in the 4th quarter valued at $43,000. Opaleye Management Inc. acquired a new stake in Jasper Therapeutics in the fourth quarter valued at about $3,144,000. Kingdon Capital Management L.L.C. grew its position in Jasper Therapeutics by 16.4% in the fourth quarter. Kingdon Capital Management L.L.C. now owns 3,540,000 shares of the company’s stock valued at $2,793,000 after acquiring an additional 500,000 shares during the last quarter. Concurrent Investment Advisors LLC acquired a new position in Jasper Therapeutics during the first quarter worth about $599,000. Finally, Russell Investments Group Ltd. bought a new position in shares of Jasper Therapeutics in the first quarter worth about $2,343,000. 79.85% of the stock is currently owned by institutional investors and hedge funds.

About Jasper Therapeutics

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.